Abstract
Lung cancer is the number one cause of cancer deaths in the United States. Prognosis is quite grim at the exception of stage 1. When faced with failure of several therapeutic regimens and rapid progression of disease, considering alternative therapies such as radiopharmaceutical therapies may be an option. We describe the case of a 36 yo young gentleman with lung adenocarcinoma whom had imaging molecular characterization of his disease with 18F-Fluorodeoxyglucose(18F-FDG), 68Ga-DOTATATE and 18F-Fluoride PET scans which were able to shed some light on molecular characterization of his disease and serve as a guide to potential targeted/personalized radiopharmaceutical therapeutic options.